An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 4, 2013, Pages 244-251

  Connor, Daniel F ^a   Grasso, Damion J ^a   Slivinsky, Michelle D ^a   Pearson, Geraldine S ^a   Banga, Alok ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANFACINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DSM-IV; EVENING DOSAGE; FAINTNESS; FUNCTIONAL DISEASE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; NAUSEA; NIGHTMARE; OUTPATIENT; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; PRESCHOOL CHILD; PSYCHOLOGIC ASSESSMENT; PSYCHOTHERAPY; RATING SCALE; SCHOOL CHILD; SEDATION; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; GUANFACINE; HUMANS; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; STRESS DISORDERS, POST-TRAUMATIC; STRESS DISORDERS, TRAUMATIC; TREATMENT OUTCOME;

EID: 84878025227     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0119     Document Type: Article

References (43)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Arnsten AF: Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 69:e89-99, 2011.
3. Arnsten AF: Development of the cerebral cortex: XIV. Stress impairs prefrontal cortical function. J Am Acad Child Adolesc Psychiatry 38:220-222, 1999.
4. Arnsten AF, Rubia K: Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry 51:356-367, 2012.
5. Arnsten AF, Scahill L, Findling RL: Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 17:393-406, 2007.
6. Arnsten AF, Wang MJ, Paspalas CD: Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron 76:223-239, 2012.
7. Bajor LA, Ticlea AN, Osser DN: The psychopharmacology algorithm project at the Harvard South Shore Program: an update on posttraumatic stress disorder. Harv Rev Psychiatry 19:240-258, 2011.
8. Biederman J, Lyne A, Sallee FR, Whitaker T: Efficacy and safety of guanfacine extended release in attention-deficit/hyperactivity disorder. 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Boston, MA, 2007.
9. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121:e73-84, 2008.
10. Bird HR, Shaffer D, Fisher P, Gould MS: The Columbia Impairment Scale (CIS): Pilot findings on a measure of global impairment for children and adolescents. Int J Methods Psychiatr Res 3:167-176, 1993.
11. Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, Neer SM: The Screen for Child Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 36:545-553, 1997.
12. Breslau N, Davis GC, Andreski P, Peterson E: Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 48:216-222, 1991.
13. Buffalari DM, Baldwin CK, See RE: Treatment of cocaine withdrawal anxiety with guanfacine: Relationships to cocaine intake and reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) 223:179-190, 2012.
14. Coccaro EF, Sripada CS, Yanowitch RN, Phan KL: Corticolimbic function in impulsive aggressive behavior. Biol Psychiatry 69:1153-1159, 2011.
15. Cohen JA, Mannarino AP, Iyengar S: Community treatment of posttraumatic stress disorder for children exposed to intimate partner violence. Arch Pediatr Adolesc Med 165:16-21, 2011.
16. Cohen JA, Mannarino AP, Perel JM, Staron V: A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry 46:811-819, 2007.
17. Connor DF, Meltzer BM: Pediatric Psychopharmacology Fast Facts. New York: W.W. Norton and Company; 2006.
18. Costello EJ, Pine DS, Hammen C, March JS, Plotsky PM, Weissman MM, Biederman J, Goldsmith HH, Kaufman J, Lewinsohn PM, Hellander M, Hoagwood K, Koretz DS, Nelson CA, Leckman JF: Development and natural history of mood disorders. Biol Psychiatry 52:529-542, 2002.
19. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Press; 1998.
20. Finkelhor D, Turner H, Ormrod R, Hamby SL: Violence, abuse, and crime exposure in a national sample of children and youth. Pediatrics 124:1411-1423, 2009.
21. Ford JD, Connor DF, Hawke J: Complex trauma among psychiatrically impaired children: A cross-sectional, chart-review study. J Clin Psychiatry 70:1155-1163, 2009.
22. Ford JD, Fraleigh LA, Connor DF: Child abuse and aggression among seriously emotionally disturbed children. J Clin Child Adolesc Psychol 39:25-34, 2010.
23. Guy W: Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976.
24. Harmon RJ, Riggs PD: Clonidine for posttraumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry 35:1247-1249, 1996.
25. Horrigan JP, Barnhill LJ: The suppression of nightmares with guanfacine. J Clin Psychiatry 57:371, 1996.
26. Jovanovic T, Ressler KJ: How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. Am J Psychiatry 167:648-662, 2010.
27. Kinzie JD, Leung P: Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 177:546-550, 1989.
28. Meiser-Stedman R, Smith P, Glucksman E, Yule W, Dalgleish T: The posttraumatic stress disorder diagnosis in preschool-and elementary school-age children exposed to motor vehicle accidents. Am J Psychiatry 165:1326-1337, 2008.
29. Muthen LK, Muthen BO: MPlus user's guide, 5th ed. Los Angeles: Muthen and Muthen; 2007.
30. Pelcovitz D, Kaplan S, Goldenberg B, Mandel F, Lehane J, Guarrera J: Post-traumatic stress disorder in physically abused adolescents. J Am Acad Child Adolesc Psychiatry 33:305-312, 1994.
31. Qasaymeh MM, Mink JW: New treatments for tic disorders. Curr Treat Options Neurol 8:465-473, 2006.
32. Ramos-Quiroga JA, Casas M: Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs 25:17-36, 2011.
33. Robb AS, Cueva JE, Sporn J, Yang R, Vanderburg DG: Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 20:463-471, 2010.
34. Robert R, Tcheung WJ, Rosenberg L, Rosenberg M, Mitchell C, Villarreal C, Thomas C, Holzer C,MeyerWJ 3rd: Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: A randomized, double-blind study. Burns 34:919-928, 2008.
35. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J: Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:155-165, 2009.
36. Seedat S, Lockhat R, Kaminer D, Zungu-Dirwayi N, Stein DJ: An open trial of citalopram in adolescents with post-traumatic stress disorder. Int Clin Psychopharmacol 16:21-25, 2001.
37. Southwick SM, Krystal JH, Bremner JD, Morgan CA, 3rd, Nicolaou AL, Nagy LM, Johnson DR, Heninger GR, Charney DS: Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 54:749-758, 1997.
38. Southwick SM, Paige S, Morgan CA, 3rd, Bremner JD, Krystal JH, Charney DS: Neurotransmitter alterations in PTSD: Catecholamines and serotonin. Semin Clin Neuropsychiatry 4:242-248, 1999.
39. Steinberg AM, Brymer MJ, Decker KB, Pynoos RS: The University of California at Los Angeles Post-traumatic Stress Disorder Reaction Index. Curr Psychiatry Rep 6:96-100, 2004.
40. Strawn JR, Geracioti TD, Jr: Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress Anxiety 25:260-271, 2008.
41. Strawn JR, Keeshin BR, Geracioti TD, DelBello MP, Putnam FW: Psychopharmacologic treatment of posttraumatic stress disorder in children and adolescents. J Clin Psychiatry 71:932-941, 2010.
42. Stoddard FJ Jr, Luthra R, Sorrentino EA, Saxe GN, Drake J, Chang Y, Levine JB, Chedekel DS, Sheridan RL: A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol 21:469-477, 2011.
43. Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, Vijayraghavan S, Brennan A, Dudley A, Nou E, Mazer JA, McCormick DA, Arnsten AF: Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129:397-410, 2007.